International journal of women's health · 2025
Nomogram-Based Prediction of Live Birth in GnRH Antagonist Protocol Fresh IVF/ICSI Cycles.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhong Yanyu, Kang Qian, Pang Xin, Wang Nan
Аннотация
OBJECTIVE: This investigation sought to determine optimal prognostic indicators and develop an implementable predictive framework for estimating live birth probabilities in subfertile individuals receiving gonadotropin-releasing hormone antagonist-based ovarian stimulation during fresh embryo transfer cycles of assisted reproductive technology.
METHODS: In this observational cohort analysis, we examined consecutive fresh in vitro fertilization/embryo transfer (IVF/ET) cycles utilizing GnRH antagonist protocols (training = 587, validation = 168 cycles; 2017-2022). Live birth rate served as the principal outcome measure. Through multivariable regression modeling, we identified key predictive variables and constructed a visual prediction tool. Model robustness was assessed using ROC-AUC metrics and decision curve validation with 500 bootstrap iterations.
RESULTS: The final predictive algorithm incorporated six clinical parameters: serum progesterone on post-ovulation day 9 (serum P (OPU+9) ≥ 51.4 ng/mL), transferred embryo count, progesterone-follicle ratio (PFR), triggering-day progesterone levels, progesterone-to-total follicle ratio, and creatinine concentrations. The training cohort demonstrated moderate discriminative capacity (ROC-AUC 0.72, 95% CI 0.68-0.76), with enhanced performance in validation samples (AUC 0.81, 95% CI 0.73-0.89). Decision curve evaluations confirmed the model's clinical applicability.
CONCLUSION: Our prognostic scoring chart offers an accessible and practical clinical instrument for estimating reproductive success in GnRH antagonist-based IVF/ICSI cycles. This tool facilitates personalized treatment planning and therapeutic strategy optimization, potentially improving resource allocation in fertility care.
METHODS: In this observational cohort analysis, we examined consecutive fresh in vitro fertilization/embryo transfer (IVF/ET) cycles utilizing GnRH antagonist protocols (training = 587, validation = 168 cycles; 2017-2022). Live birth rate served as the principal outcome measure. Through multivariable regression modeling, we identified key predictive variables and constructed a visual prediction tool. Model robustness was assessed using ROC-AUC metrics and decision curve validation with 500 bootstrap iterations.
RESULTS: The final predictive algorithm incorporated six clinical parameters: serum progesterone on post-ovulation day 9 (serum P (OPU+9) ≥ 51.4 ng/mL), transferred embryo count, progesterone-follicle ratio (PFR), triggering-day progesterone levels, progesterone-to-total follicle ratio, and creatinine concentrations. The training cohort demonstrated moderate discriminative capacity (ROC-AUC 0.72, 95% CI 0.68-0.76), with enhanced performance in validation samples (AUC 0.81, 95% CI 0.73-0.89). Decision curve evaluations confirmed the model's clinical applicability.
CONCLUSION: Our prognostic scoring chart offers an accessible and practical clinical instrument for estimating reproductive success in GnRH antagonist-based IVF/ICSI cycles. This tool facilitates personalized treatment planning and therapeutic strategy optimization, potentially improving resource allocation in fertility care.